<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04910698</url>
  </required_header>
  <id_info>
    <org_study_id>Antibioshort neutropenia</org_study_id>
    <nct_id>NCT04910698</nct_id>
  </id_info>
  <brief_title>Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia</brief_title>
  <official_title>Efficacy of Antibiotic Short Course for Bloodstream Infections in Acute Myeloid Leukemia Patients With Febrile Neutropenia: a Retrospective Comparative Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Poitiers University Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Poitiers University Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      There is no specific recommendation about antimicrobial treatment length for documented&#xD;
      infections in chemotherapy induced febrile neutropenia. The aim of this study was to compare&#xD;
      long versus short antibiotic course for bloodstream infection treatment in acute myeloid&#xD;
      leukemia patients during febrile neutropenia. This monocentric retrospective comparative&#xD;
      study included all consecutive bloodstream infection episodes among acute myeloid leukemia&#xD;
      patients with febrile neutropenia for 3 years (2017-2019). Episodes were classified regarding&#xD;
      the length of antibiotic treatment, considered as short course if the treatment lasted ≤7&#xD;
      days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which&#xD;
      the threshold was ≤10 days and ≤14 days, respectively. The primary outcome was the number of&#xD;
      bloodstream infection relapses in both groups within 30 days of antibiotic discontinuation.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Completed</overall_status>
  <start_date type="Actual">January 1, 2020</start_date>
  <completion_date type="Actual">June 1, 2020</completion_date>
  <primary_completion_date type="Actual">June 1, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Retrospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bloodstream infection relapses</measure>
    <time_frame>within 30 days of antibiotic discontinuation</time_frame>
    <description>The primary outcome was to compare the number of bloodstream infection relapses in both groups within 30 days of antibiotic discontinuation.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mortality</measure>
    <time_frame>within 30 days of antibiotic discontinuation</time_frame>
    <description>Comparison of mortality rate within 30 days of antibiotic discontinuation</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Epidemiology of bacteria</measure>
    <time_frame>at baseline</time_frame>
    <description>Distribution of bacteria responsible for bloodstream infection</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Risk factors for relapses</measure>
    <time_frame>within 30 days of antibiotic discontinuation</time_frame>
    <description>Analyse of risk factors for bloodstream infection relapses</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Actual">104</enrollment>
  <condition>Bloodstream Infection</condition>
  <condition>Acute Myeloid Leukemia</condition>
  <condition>Febrile Neutropenia</condition>
  <arm_group>
    <arm_group_label>Short course treatment</arm_group_label>
    <description>Patients who received antibiotic for 7 or less days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Long course treatment</arm_group_label>
    <description>Patients who received antibiotic for more than 7 days, except for nonfermenting bacteria and Staphylococcus aureus or lugdunensis for which the threshold was 10 days and 14 days, respectively.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Antibiotic</intervention_name>
    <description>Antibiotic duration of treatment defined if the patient belonged to long course or short course group.</description>
    <arm_group_label>Long course treatment</arm_group_label>
    <arm_group_label>Short course treatment</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        All bloodstream infection episodes occuring in patients suffering from febrile neutropenia&#xD;
        during acute myeloid leukemia between January 2017 and December 2019 in University Hospital&#xD;
        of Poitiers were included.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Acute myeloid leukemia&#xD;
&#xD;
          -  chemo-induced febrile neutropenia&#xD;
&#xD;
          -  Bloodstream infection&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  lack of data&#xD;
&#xD;
          -  endovascular infections&#xD;
&#xD;
          -  surgical treatment required&#xD;
&#xD;
          -  central nervous system infections&#xD;
&#xD;
          -  antibiotic treatment &lt; 4 days&#xD;
&#xD;
          -  death before the end of antibiotic treatment&#xD;
&#xD;
          -  unappropriated antibiotic treatment at 48h&#xD;
&#xD;
          -  relapses of bloodstream infection episodes already included&#xD;
&#xD;
          -  hematopoietic stem cell transplant&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>France Cazenave-Roblot</last_name>
    <role>Study Director</role>
  </overall_official>
  <location>
    <facility>
      <name>University Hospital</name>
      <address>
        <city>Poitiers</city>
        <zip>86000</zip>
        <country>France</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>May 2021</verification_date>
  <study_first_submitted>May 27, 2021</study_first_submitted>
  <study_first_submitted_qc>June 1, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">June 2, 2021</study_first_posted>
  <last_update_submitted>June 1, 2021</last_update_submitted>
  <last_update_submitted_qc>June 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">June 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>antibiotic short course, appropriate use of antibiotics</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Infections</mesh_term>
    <mesh_term>Communicable Diseases</mesh_term>
    <mesh_term>Sepsis</mesh_term>
    <mesh_term>Leukemia</mesh_term>
    <mesh_term>Leukemia, Myeloid</mesh_term>
    <mesh_term>Leukemia, Myeloid, Acute</mesh_term>
    <mesh_term>Neutropenia</mesh_term>
    <mesh_term>Febrile Neutropenia</mesh_term>
    <mesh_term>Hyperthermia</mesh_term>
    <mesh_term>Fever</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Anti-Bacterial Agents</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

